Preoperative vs Postoperative Intravitreal Aflibercept Injection for the Management of Diabetic Macular Edema in Patients Undergoing Cataract Surgery
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- AAO 2023: Aflibercept 8 mg Effective Across Demographic Subgroups for Diabetic Macular Edema
- Aflibercept for DME
- ASRS 2023: Greater Frequency of Intravitreal Aflibercept Injections May Benefit Patients With Diabetic Macular Edema
- Predictors of Treatment Outcomes Following a Treat-and-Extend Regimen With Aflibercept in Patients With Branch Retinal Vein Occlusion
- ASRS 2023: Proposed Biosimilar Demonstrates Similar Efficacy to Aflibercept for Diabetic Macular Edema
- Angiographic Biomarkers Significantly Predict Treatment Response to Intravitreal Aflibercept in Patients With Diabetic Macular Edema
Graefe's Archive for Clinical and Experimental Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pre-operative versus post-operative intravitreal aflibercept injection for management of DME in patients undergoing cataract surgery
Graefes Arch. Clin. Exp. Ophthalmol 2023 Nov 01;261(11)3223-3229, AM Khattab, SM Hagras, NM LotfyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.